Evidence map›Paper›PMID 41386518›Full record

ArticleNeuroscience2026

Impact of cardiometabolic factors and AD plasma biomarkers on white matter hyperintensities volume in individuals with cognitive complaints from the global south.

Patricio Riquelme-Contreras, Fernando Henriquez, Cecilia Gonzalez-Campo, Florencia Altschuler, Matías Fraile-Vazquez, Pamela C L Ferreira, Bruna Bellaver, Thomas K Karikari, Tharick A Pascoal, Cecilia Okuma and 8 more

Abstract read
In one paragraph

Article in Neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Patricio Riquelme-ContrerasDepartment of Medical Technology. Faculty of Medicine. Universidad de Chile, Chile; Geroscience Center for Mental Health and Metabolism (GERO Chile), Chile; Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - Institute of Biomedical Science, Universidad de Chile, Chile; PhD in Sciences / Neuroscience Program. Faculty of Sciences. Universidad de Valparaíso, Chile.
Fernando HenriquezGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile; Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - Institute of Biomedical Science, Universidad de Chile, Chile; Laboratory for Cognitive and Evolutionary Neuroscience (LaNCE), Department of Psychiatry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Chile.
Cecilia Gonzalez-CampoCognitive Neuroscience Center, Universidad de San Andrés, Argentina; National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Florencia AltschulerCognitive Neuroscience Center, Universidad de San Andrés, Argentina; National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Matías Fraile-VazquezCognitive Neuroscience Center, Universidad de San Andrés, Argentina; National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Pamela C L FerreiraDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Bruna BellaverDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Thomas K KarikariDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Tharick A PascoalDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Cecilia OkumaGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile.
Christian Gonzalez-BillaultGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile; Buck Institute for Research on Aging, Novato, CA, USA.
Felipe A CourtGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile; Center for Aging Research and Healthy Longevity, Faculty of Sciences, Universidad Mayor, Santiago, Chile; Buck Institute for Research on Aging, Novato, CA, USA; Centro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Santiago, Chile.
Mauricio CerdaGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile; Integrative Biology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine. Universidad de Chile, Chile.
Patricia LilloGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile.
Claudia Durán-AniotzLatin American Brain Health Institute (BrainLat), Universidad Adolfo Ibanez, Santiago, Chile; Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland.
Mizanur KhondokerNorwich Medical School, University of East Anglia, Norwich, UK.
Michael HornbergerClinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton. UK. Electronic address: M.Hornberger@soton.ac.uk.
Andrea SlachevskyGeroscience Center for Mental Health and Metabolism (GERO Chile), Chile; Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - Institute of Biomedical Science, Universidad de Chile, Chile; Neuroscience and East Neurological Sciences Departments, Faculty of Medicine, Universidad de Chile, Chile; Memory and Neuropsychiatric Center (CMYN). Neurology Department, Hospital del Salvador and Faculty of Medicine, Universidad de Chile, Chile; Neurology and Psychiatry Department, Clínica Alemana - Universidad del Desarrollo, Santiago, Chile. Electronic address: andrea.slachevsky@uchile.cl.

Funding

US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
NIA NIH HHS R01 AG057234
6 · The paper itself

Abstract

White matter hyperintensities (WMH) are a magnetic resonance imaging (MRI) sign associated with cognitive complaints in the Alzheimer's Disease (AD) continuum, including the pre-dementia steps. Cardiovascular and neurodegenerative pathophysiology have been postulated as relevant factors in the origin of WMH in AD. However, this evidence comes mainly from northern global populations, where the epidemiological profile differs from other geographical regions. This study explores the relationship between WMH, cardiometabolic and plasma neurodegeneration biomarkers in individuals with cognitive complaints from a developing country in the global south, where cardiometabolic risk factors are highly prevalent. We analyzed 112 individuals with cognitive complaints, assessing plasma pTau217, Aβ42/Aβ40 ratio, blood pressure, and glycemia levels while quantifying and segmenting WMH volumes. Multiple regression analyses revealed that diastolic blood pressure was significantly associated with WMH in specific white matter tracts, including the anterior thalamic radiation, cingulum, forceps minor, and subcortical regions. In contrast, no associations were found with glycemia, pTau217, Aβ42/40, or systolic blood pressure. These findings suggest that cardiovascular factors could be more critical in WMH development than neurodegeneration markers in this population. Our study, in addition to reflecting, in part, the associations between cardiovascular risk factors and WMH, highlights the need for further research on neurovascular contributions to dementia pathophysiology in these populations, emphasizing the role of neurovascular integrity, blood-brain barrier function, and cerebrospinal fluid circulation in underrepresented geographical contexts.

Indexed as

Alzheimer DiseaseCardiometabolic Risk FactorsCognitive DysfunctionWhite MatterAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBlood GlucoseBlood PressureBrainFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAmyloid beta-PeptidesBiomarkersBlood GlucosePeptide Fragmentstau ProteinsCardiometabolic factorsDementia-free cognitive complaint individualsNeurodegeneration blood biomarkersWhite matter hyperintensities

Identifiers

PMID41386518
PMCPMC13182573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.